FINWIRES · TerminalLIVE
FINWIRES

Ingenia Therapeutics Goes Public on KOSDAQ

By

Ingenia Therapeutics, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.

Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.

Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.

The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.

The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease (currently in mid-stage patient trials) and IGT-532 for solid tumors

Related Articles

Asia

Wasco Greenergy Appoints Group MD as CEO Opts for Early Retirement

Wasco Greenergy (KLSE:GENERGY) said its chief executive officer, Lee Yee Chong, opted for early retirement from the role, effective Dec. 31, according to a Monday filing with Bursa Malaysia.Shares slid over 2% in Tuesday's late morning trade.Lee joined the group in 1995 and has held several key leadership positions within Wasco over the years.The company appointed Wong Yin Kee as group managing director, effective Aug. 17, to facilitate the transition of authority and responsibilities.

KLSE:GENERGY
Asia

Yuntianhua's H1 Profit Rises 6%, Revenue Drops 9%; Shares Up 3%

Yunnan Yuntianhua's (SHA:600096) net profit attributable to shareholders for the first half rose 6.1% to 2.93 billion yuan from 2.76 billion yuan a year earlier, according to a Tuesday disclosure on the Shanghai bourse.Earnings per share increased year on year to 1.61 yuan from 1.52 yuan.Operating revenue fell 8.9% to 22.8 billion yuan from 25.1 billion yuan in the previous year.The board of directors proposed a cash dividend of 2 yuan for every 10 shares.The high-quality diammonium phosphate supplier's shares rose nearly 3% during the morning trade.

SHA:600096
Asia

Market Chatter: CJ Group Sets KRW12 Trillion Revenue Target for North America by 2028

CJ Group expects its total revenue from North America to expand to 12 trillion won by 2028, driven by rising demand for Korean food, entertainment, and beauty products, The Korean Times reported Monday.The South Korean group, led by holding company CJ (KRX:001040), unveiled its target following a strategy meeting with the group chairman in Los Angeles last week.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

KRX:001040